Suppl. Fig.S7. Effects of alendronate (ALN), an endocytosis inhibitor (dansylcadaverine, DC), and a mevalonate pathway intermediate (geranylgeraniol, GO), on relative levels of osteocalcin mRNA (A) and osteocalcin positive cell number (B) of rat primary osteoblastic cells at day 21. Cells were treated with $10^{-6}$ M or $10^{-5}$ M ALN with or without 20 μM GO or 100 μM DC from day 3 to day 6. Each column + bar represents the mean + 1 SD. Significant difference from control: ** p<0.01, * p<0.05.